In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...

STOCKHOLM -- The sodium glucose co-transporter 2 (SGLT2) class of diabetes medications may offer more protection against diabetic retinopathy as compared with other hypoglycemic agents, an analysis of ...

Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...

Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...

Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).

Modestly lower risk for depression seen compared with DPP-4i use, but not compared with SGLT-2i use. (HealthDay News) — For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 ...